Serotonin syndrome and the triptans
Serotonin syndrome (SS) is a potentially life-threatening adverse drug reaction that can result from interaction between two or more serotoninergic drugs and even from the use of a single serotoninergic drug. This condition is an acute toxic reaction to substances that enhance serotoninergic activit...
| Autores: | , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2013 |
| País: | Brasil |
| Institución: | Sociedade Brasileira de Cefaleia |
| Repositorio: | Revista Headache Medicine (Online) |
| Idioma: | inglés |
| OAI Identifier: | oai:ojs.pkp.sfu.ca:article/365 |
| Acceso en línea: | https://headachemedicine.com.br/index.php/hm/article/view/365 |
| Access Level: | acceso abierto |
| Palabra clave: | Síndrome serotoninérgica Toxicidade Interaçõoes farmacolóogicas Triptanas Inibidores da receptação da serotonina Inibidores da recaptação adrenérgica Agonistas dos receptores serotonérgicos Serotonin syndrome toxicity drug interactions triptans serotonin reuptake inhibitors adrenergic reuptake inhibitors serotonin receptors agonists |
| Sumario: | Serotonin syndrome (SS) is a potentially life-threatening adverse drug reaction that can result from interaction between two or more serotoninergic drugs and even from the use of a single serotoninergic drug. This condition is an acute toxic reaction to substances that enhance serotoninergic activity at certain synapses either within the central or the periphery. Clinical features of SS consist of the triad: altered mental status, autonomic hyperactivity and neuromuscular abnormalities. The severity of SS cases ranges from mild to fatal. This syndrome has a rapid onset and, in most of the cases, is a self-limiting condition that improves on cessation of the offending drugs. In 2006, US Food and Drug Administration (FDA) issued an alert about the presumptive ocurrence of SS with combined use of triptans and selective serotonin re-uptake inhibitors or selective serotonin/norepinephrine re-uptake inhibitors (The so called dual selective inhibitors). Nonetheless, despite this statement, insufficient data are available to judge whether this combination actually increases the risk of serotonin syndrome. |
|---|